Reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies Reauthorization of the Support Act.
2025 · 2nd Quarter (Apr 1 - June 30)
BRAEBURN PHARMACEUTICALS, INC.
Filed by STANTON PARK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- STANTON PARK GROUP
- Filing UUID
- 970fb69a-cfcf-487b-b910-1dbaf9adabd6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.